Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jinlong capsule is a Traditional Chinese Medicine (TCM) formulation primarily composed of animal-derived ingredients, specifically the freeze-dried powder of three types of snakes: *Bungarus multicinctus* (many-banded krait), *Agkistrodon acutus* (long-nosed pit viper), and *Naja naja* (cobra). It was originally developed and is widely used in China as an adjuvant therapy for various malignancies, including primary liver cancer, due to its purported anti-tumor and immunomodulatory properties. In the context of HIV/AIDS research, it is evaluated for its ability to stabilize or increase CD4+ T-lymphocyte counts and improve the immune function of asymptomatic HIV-infected individuals. The mechanism is thought to involve the regulation of the immune system and potential inhibition of viral replication, though it is typically used as part of a syndrome-differentiated treatment approach in TCM.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jinlong capsule.